These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 12675865

  • 1. Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis.
    Fadia A, Casserly LF, Sanchorawala V, Seldin DC, Wright DG, Skinner M, Dember LM.
    Kidney Int; 2003 May; 63(5):1868-73. PubMed ID: 12675865
    [Abstract] [Full Text] [Related]

  • 2. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RH, Berk J, Quillen K, Skinner M.
    Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
    [Abstract] [Full Text] [Related]

  • 3. Microbiologically documented infections in patients undergoing high-dose melphalan and autologous stem cell transplantation for the treatment of light chain amyloidosis.
    Taimur S, Nader C, Lloyd-Travaglini C, Seldin DC, Sanchorawala V.
    Transpl Infect Dis; 2013 Apr; 15(2):187-94. PubMed ID: 23279695
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Predictors and outcomes of acute kidney injury during autologous stem cell transplantation in AL amyloidosis.
    Nader R, Zhen A, Angel-Korman A, Pavlovich SS, Pogrebinsky A, Doros G, Menn-Josephy H, Stern L, Sanchorawala V, Havasi A.
    Nephrol Dial Transplant; 2022 Jun 23; 37(7):1281-1288. PubMed ID: 34043009
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease.
    Casserly LF, Fadia A, Sanchorawala V, Seldin DC, Wright DG, Skinner M, Dember LM.
    Kidney Int; 2003 Mar 23; 63(3):1051-7. PubMed ID: 12631087
    [Abstract] [Full Text] [Related]

  • 8. The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation.
    Leung N, Kumar SK, Glavey SV, Dispenzieri A, Lacy MQ, Buadi FK, Hayman SR, Dingli D, Kapoor P, Zeldenrust SR, Russell SJ, Lust JA, Hogan WJ, Rajkumar SV, Gastineau DA, Kourelis TV, Lin Y, Gonsalves WI, Go RS, Gertz MA.
    Nephrol Dial Transplant; 2016 Aug 23; 31(8):1284-9. PubMed ID: 26627634
    [Abstract] [Full Text] [Related]

  • 9. [Clinical analysis of autologous stem cell transplantation for nine cases of cardiac amyloidosis].
    Ogura M, Sekine R, Nishiyama S, Abe Y, Iizuka H, Kusaka S, Nakagawa Y, Suzuki K.
    Rinsho Ketsueki; 2012 Jul 23; 53(7):710-5. PubMed ID: 22975774
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome.
    Bergesio F, Ciciani AM, Manganaro M, Palladini G, Santostefano M, Brugnano R, Di Palma AM, Gallo M, Rosati A, Tosi PL, Salvadori M, Immunopathology Group of the Italian Society of Nephrology.
    Nephrol Dial Transplant; 2008 Mar 23; 23(3):941-51. PubMed ID: 17951308
    [Abstract] [Full Text] [Related]

  • 13. Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation.
    Leung N, Slezak JM, Bergstralh EJ, Dispenzieri A, Lacy MQ, Wolf RC, Gertz MA.
    Am J Kidney Dis; 2005 Jan 23; 45(1):102-11. PubMed ID: 15696449
    [Abstract] [Full Text] [Related]

  • 14. Renal failure in the ICU: comparison of the impact of acute renal failure and end-stage renal disease on ICU outcomes.
    Clermont G, Acker CG, Angus DC, Sirio CA, Pinsky MR, Johnson JP.
    Kidney Int; 2002 Sep 23; 62(3):986-96. PubMed ID: 12164882
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.
    Sanchorawala V, Wright DG, Quillen K, Finn KT, Dember LM, Berk JL, Doros G, Fisher C, Skinner M, Seldin DC.
    Bone Marrow Transplant; 2007 Sep 23; 40(6):557-62. PubMed ID: 17589534
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
    Frossard V, Ketterer N, Rosselet A, Meier P, Cairoli A, Duchosal MA, Kovacsovics T.
    Ann Hematol; 2009 Jul 23; 88(7):681-5. PubMed ID: 19066891
    [Abstract] [Full Text] [Related]

  • 20. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study.
    Bird JM, Fuge R, Sirohi B, Apperley JF, Hunter A, Snowden J, Mahendra P, Milligan D, Byrne J, Littlewood T, Fegan C, McQuaker G, Pagliuca A, Johnson P, Rahemtulla A, Morris C, Marks DI, British Society of Blood and Marrow Transplantation.
    Br J Haematol; 2006 Aug 23; 134(4):385-90. PubMed ID: 16822294
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.